Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up on Strong Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC)’s share price gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $36.09, but opened at $39.39. Phibro Animal Health shares last traded at $36.3350, with a volume of 35,419 shares changing hands.

The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $396.75 million during the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is 20.60%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Citigroup lowered their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.50.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently made changes to their positions in PAHC. 1620 Investment Advisors Inc. increased its holdings in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares in the last quarter. Farther Finance Advisors LLC raised its position in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares during the last quarter. KBC Group NV purchased a new stake in shares of Phibro Animal Health during the 1st quarter valued at about $29,000. Rothschild Investment LLC grew its stake in shares of Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health in the third quarter worth approximately $61,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Price Performance

The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm’s fifty day moving average price is $33.95 and its two-hundred day moving average price is $42.44. The stock has a market capitalization of $1.45 billion, a PE ratio of 15.19, a PEG ratio of 0.51 and a beta of 0.46.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.